ValiRx plc (GB:VAL) has released an update.
ValiRx plc’s subsidiary, Inaphaea BioLabs Limited, has entered into a lucrative agreement with DLOC Biosystems Holdings Limited to supply its Patient Derived Cells for the development of advanced cancer tumor models using organ-on-a-chip technology. The partnership, which focuses on glioblastoma and Triple Negative Breast Cancer models, is set to bolster drug development efficiencies and reduce reliance on animal testing. ValiRx anticipates this collaboration will accelerate their drug candidate pipeline and enhance their biobank’s commercial prospects.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
